

GAN

PDB:2PPI

Revision

Revision Type:created

Revised by:created

Revision Date:created

Entry Clone Accession:gi|11545731

Entry Clone Source:MGC

SGC Clone Accession:GANA-c010

Tag:Tag sequence: mhhhhhssgvdlgtenlyfq*s(m) TEV-cleavable (*) N-terminal his6 tag.

Host:BL21(DE3)-R3-pRARE2

Construct

Prelude:

Sequence:

mhhhhhssgvdlgtenlyfq*smAVSDPQHAARLLRALSSFREESRFCD AHLVLDGEEIPVQKNILAAASPYIRTKLNYNPPKDDG
STYKIELEGISVMVMREILDYIFSGQIRLNEDTIQDVVQAADLLLLTDLKTLCCFLE

Vector:pNIC28-Bsa4.

Growth

Medium:LB

Antibiotics:

Procedure:Starter cultures (10 ml LB, 50 µg/ml kanamycin) were inoculated from a glycerol stock and grown overnight. LB media (1L) was inoculated with 5 ml of culture and grown at 37°C, 170 rpm until OD600 was 0.4. The flask was then transferred to an 18°C incubator and protein expression induced with 0.1 mM IPTG (final concentration) at an OD600 of approximately 0.5. Cells were harvested the following morning by centrifugation (10min, 6500rp, 4°C). The pellet was resuspended in 25 ml binding buffer and frozen at -20°C.

Purification

Procedure

Column 1: DE52 anion exchange resin/ IMAC Sepharose 6 Fast Flow resin, placed in series.

Column 2: Gel Filtration, HiLoad 16/60 Superdex 75 prep grade column run on an AKTA-prime system.

Procedure (Gravity feed chromatography): DE52 anion exchange resin was prepared by suspending 10 g in 100 ml of 2.5 M NaCl. The resulting gel slurry was packed in a column and allowed to settle prior to equilibrating in approximately 50 mls of Binding Buffer. Nickel charged IMAC sepharose beads were prepared by packing 4 mls of gel slurry (approximately 50% beads in 30% EtOH) in a small column and equilibrating in approximately 10 mls of Binding Buffer. Both columns were then placed in series and the protein containing supernatant passed through under gravity. This was followed by washing using 50 mls of Binding Buffer followed by 50 mls of Wash Buffer. Elution of the protein proceeded using a stepwise gradient of elution buffer: 5 mls x 30 mM imidazole, 5 mls x 50 mM imidazole and 10 mls x 250 mM imidazole.

Enzymatic treatment: Protein containing fractions were pooled and the His-tag cleaved using TEV protease (reaction proceeded overnight at 4°C).

Procedure (Gel Filtration): The protein solution was concentrated using a Vivaspin 20 ultrafiltration device with a 5 kDa MWCO to about 10 ml. A pre-equilibrated gel filtration column was injected with 2 ml of the solution and two runs undertaken at a flow rate of 0.8 ml/min.

Extraction

Procedure

The cell pellet was defrosted and cells were lysed by sonication, 10 s on, 2 s off at 40% amplitude for 8 min. The lysate was cleared by centrifugation for 45 minutes at 21,500 RPM, 4°C.

Concentration: Using Vivaspin 5 ultrafiltration spin columns with a 5 kDa MWCO the protein was dialysed against 50 mM HEPES, pH 7.5, 150 mM NaCl, 0.5 mM TCEP and concentrated to 12 mg/ml approximated using UV absorbance at 280 nm and a predicted extinction coefficient of 7,450.

Ligand

MassSpec: The calculated mass for this construct was 16325.5 Da. This correlated well with the mass spec data (16,324.4 Da) following TEV treatment of the protein.

Crystallization: Crystals were obtained using the vapor diffusion method. The protein was concentrated in gelfiltration buffer to a protein concentration of 12 mg/ml by mixing 100nl of the concentrated protein with 50nl of a well solution containing the following salt additive mix: 0.1 M NaNO₃, 0.1M Na₂SO₄, 0.05 M Na/KPO₄, 0.0285 M (NH)₂SO₄ adjusted to pH 6.0 and precipitating agents: 30% PEG3350 and 10% Ethylene glycol. Crystallization experiments were setup at 4°C.

NMR Spectroscopy:

Data Collection: Crystals were cryo-protected using the well solution supplemented with an additional 25% ethylene glycol and flash frozen in liquid nitrogen. Diffraction data were collected at the SLS beam line X10 ($\lambda = 0.978 \text{ \AA}$) to 2.4 Å.

Data Processing:

